Vanda Pharmaceuticals Inc. (VNDA) Q4 FY25 Earnings Call

FNAP momentum supports 2026 growth, but generic pressure and higher cash burn remain material offsets.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-16
Length51 minutes
EPS$-0.46
Revenue$56.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All VNDA earnings ยท Back to VNDA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.